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The authors are retracting this Article. The Article comprises three parts: a case-control study; a meta-analysis of case-control studies; and Mendelian randomization (MR) analyses (two datasets; a Japanese dataset and a public genome-wide association study \[GWAS\]-pooled dataset). In the MR analysis using the public dataset, the authors mistook effect alleles, resulting in incorrect results (Figure 3) and conclusion.

Our updated MR results are as follows: odds ratio (OR)scz/crp 0.87 (95% CI 0.76--1.00, p = 0.046) using rs2794520; 0.83 (95% CI 0.72--0.96, p = 0.014) using rs1183910; 0.85 (95% CI 0.77--0.94, p = 0.0017) across these two single nucleotide polymorphisms (SNPs); and 0.89 (95% CI 0.82--0.97, p = 0.006) using 15 C-reactive protein (CRP)-associated SNPs, which reached genome-wide significance in a meta-analysis of GWAS, respectively. These updated results of the MR analysis using the limited number of SNPs indicate a protective causal association between elevated CRP levels and schizophrenia risk. Therefore, the hypothesis in the conclusion of the Article---that medications which reduce CRP levels can be used in schizophrenia---is not supported.

All authors recognize these miscalculations in the original MR analysis and have agreed to the retraction of this Article.
